MCID: BRY005
MIFTS: 45

Beryllium Disease

Categories: Rare diseases, Respiratory diseases

Aliases & Classifications for Beryllium Disease

MalaCards integrated aliases for Beryllium Disease:

Name: Beryllium Disease 53 73
Subacute Berylliosis 53 73
Acute Berylliosis 53 73
Chronic Pulmonary Berylliosis 53
Reversible Berylliosis 53
Beryllliosis 53

Classifications:



External Ids:

Summaries for Beryllium Disease

NIH Rare Diseases : 53 The following summary is from Orphanet, a European reference portal for information on rare diseases and orphan drugs.Orpha Number: 133Disease definitionChronic beryllium disease (CBD) is a granulomatous, interstitial lung disease that occurs in individuals who develop beryllium sensitization (BeS), a cell-mediated immune response to environmental and occupational beryllium exposure. BeS precedes the lung disease that may present with chronic dry cough, fatigue, weight loss, chest pain, and increasing dyspnea.EpidemiologyThe number of workers exposed to beryllium has been estimated at 1 million in the US, although no accurate figure exists for the US or globally. The prevalence of sensitization in those exposed ranges from 1 - 20%. CBD among those with BeS ranges from 15-100%.Clinical descriptionPatients with CBD can range from those who are asymptomatic to those with severe lung dysfunction. Manifestations occur a few months to a many years after exposure to beryllium and include chronic dry cough, dyspnea on exertion, chest pain, fatigue, fever, night sweats and weight loss. Additional extrapulmonary manifestations of dermatitis and skin granulomas have been reported. Progressive pulmonary fibrosis can eventually lead to cor pulmonale and respiratory failure. An increased risk of lung cancer among workers exposed to high levels of beryllium has also been observed.EtiologyCBD is caused by occupational exposure to beryllium and beryllium-containing alloys (usually by inhalation of dust or fumes but also via contact with skin). Over time, in a subset of individuals, a cell-mediated immune response to beryllium may occur, causing the development of sensitized T cells that accumulate within the lungs and eventually form granulomas which can lead to fibrosis. A genetic variant in the HLA-DPB1 gene (6p21.3) with the presence of a glutamic acid at amino acid position 69 has been associated with the development of BeS and CBD.Diagnostic methodsDiagnosis is based on a history of exposure to beryllium, characteristic clinical findings and laboratory testing. BeS can be detected with the beryllium lymphocyte proliferation test (BeLPT) where mononuclear cells from peripheral blood or bronchoalveolar lavage are exposed to beryllium in vitro. Increased proliferation of lymphocytes compared to control cells indicates BeS. Granulomatous and/or mononuclear cell infiltrates in lung tissue, are indicative of CBD. Chest x-ray, CT scan of the lungs, exercise tolerance testing and pulmonary function tests can also aid in the diagnosis.Differential diagnosisThe main differential diagnoses are sarcoidosis (most common) and tuberculosis (see these terms) as well as other occupational lung diseases (i.e. silicosis).Management and treatmentThere is no cure for CBD. Treatment involves cessation of beryllium exposure and use of corticosteroids (prednisone). Early symptomatic disease may be treated with inhaled corticosteroids along with a short acting bronchodilator. Methotrexate and other immunosuppressive therapies can reduce steroid side effects. The efficacy of corticosteroids may be limited and relapses can occur after cessation of therapy or when dose is lowered. Those with advanced disease and major breathing difficulties may require oxygen supplementation. In severe cases, a lung transplant may be suggested. Patients should refrain from smoking. CBD may be prevented by providing exposed workers with respiratory protective devices and protective clothing and by minimizing exposure through use of workplace administration and engineering controls. The BeLPT is used to identify patients early on and to define workplace areas for modification in order to ultimately reduce additional BeS and CBD casesPrognosisPrognosis varies, with some patients remaining clinically stable for many years and some experiencing a gradual worsening of symptoms over time. A debilitating course resulting in respiratory failure is also possible but regular monitoring and treatment can slow down the disease process.Visit the Orphanet disease page for more resources.

MalaCards based summary : Beryllium Disease, also known as subacute berylliosis, is related to chronic beryllium disease and berylliosis. An important gene associated with Beryllium Disease is HLA-DPB1 (Major Histocompatibility Complex, Class II, DP Beta 1), and among its related pathways/superpathways are Innate Immune System and Activated PKN1 stimulates transcription of AR (androgen receptor) regulated genes KLK2 and KLK3. The drugs Infliximab and Mesalamine have been mentioned in the context of this disorder. Affiliated tissues include lung, t cells and testes.

CDC : 3 Go to OSHA’s web site at https://www.osha.gov/berylliumrule/index.htmlExternal to learn about the final rule in place to protect workers from Beryllium exposure. The new rule represents an example of how NIOSH research on beryllium has had a real impact in the workplace to reduce exposures and disease. The findings of NIOSH research contributed to a rule that will lower exposures and reduce disease related to beryllium in workplace across the country. 

Wikipedia : 76 Berylliosis, or chronic beryllium disease (CBD), is a chronic allergic-type lung response and chronic... more...

Related Diseases for Beryllium Disease

Diseases in the Beryllium Disease family:

Chronic Beryllium Disease

Diseases related to Beryllium Disease via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 106)
# Related Disease Score Top Affiliating Genes
1 chronic beryllium disease 33.1 HLA-DPA1 HLA-DPB1 HLA-DQB1 HLA-DRB1 TNF
2 berylliosis 32.0 HLA-DPA1 HLA-DPB1 HLA-DRB1
3 neonatal lupus erythematosus 10.1 HLA-DPB1 HLA-DQA1
4 lung cancer 10.1
5 achalasia, familial esophageal 10.1 HLA-DQA1 HLA-DQB1
6 congenital toxoplasmosis 10.1 HLA-DQA1 HLA-DQB1
7 cervical dystonia 10.1 HLA-DQA1 HLA-DQB1
8 limbic encephalitis with lgi1 antibodies 10.0 HLA-DQB1 HLA-DRB1
9 neuromyelitis optica 10.0 HLA-DPB1 HLA-DRB1
10 dermatitis herpetiformis 10.0 HLA-DQA1 HLA-DQB1
11 narcolepsy 2 10.0 HLA-DQB1 HLA-DRB1
12 autoimmune polyglandular syndrome type 3 10.0 HLA-DQB1 HLA-DRB1
13 hypersomnia 10.0 HLA-DQB1 HLA-DRB1
14 metal allergy 10.0 HLA-DQB1 HLA-DRB1
15 lichen planopilaris 10.0 HLA-DQB1 HLA-DRB1
16 type ii mixed cryoglobulinemia 10.0 HLA-DQB1 HLA-DRB1
17 recurrent respiratory papillomatosis 10.0 HLA-DQB1 HLA-DRB1
18 narcolepsy 1 10.0 HLA-DQB1 HLA-DRB1
19 hirata disease 10.0 HLA-DQA1 HLA-DRB1
20 lichen sclerosus 10.0 HLA-DQB1 HLA-DRB1
21 whipple disease 10.0 HLA-DQB1 HLA-DRB1
22 pityriasis rosea 10.0 HLA-DQB1 HLA-DRB1
23 eosinophilia-myalgia syndrome 10.0 HLA-DQA1 HLA-DRB1
24 pediatric multiple sclerosis 10.0 HLA-DQB1 HLA-DRB1
25 osteonecrosis of the jaw 10.0 HLA-DQB1 HLA-DRB1
26 myelitis 10.0 HLA-DPB1 TNF
27 histoplasmosis 10.0 HLA-DQA1 HLA-DRB1
28 peanut allergy 10.0 HLA-DQB1 HLA-DRB1
29 ocular cicatricial pemphigoid 10.0 HLA-DQB1 HLA-DRB1
30 paraneoplastic pemphigus 10.0 HLA-DQB1 HLA-DRB1
31 inflammatory bowel disease 3 10.0 HLA-DPA1 TNF
32 pulmonary sarcoidosis 10.0
33 hyperuricemia 10.0
34 extrinsic allergic alveolitis 10.0
35 lung disease 10.0
36 idiopathic achalasia 10.0 HLA-DQB1 TNF
37 cardiac sarcoidosis 10.0 HLA-DQB1 TNF
38 autoimmune hepatitis 10.0 HLA-DQB1 HLA-DRB1
39 sialadenitis 9.9 HLA-DQB1 TNF
40 cytomegalovirus retinitis 9.9 HLA-DQB1 TNF
41 microscopic polyangiitis 9.9 HLA-DRB1 TNF
42 anca-associated vasculitis 9.9 HLA-DRB1 TNF
43 actinic prurigo 9.9 HLA-DRB1 TNF
44 nontuberculous mycobacterial lung disease 9.9 HLA-DRB1 TNF
45 central nervous system vasculitis 9.9 HLA-DRB1 TNF
46 rheumatoid vasculitis 9.9 HLA-DRB1 TNF
47 guillain-barre syndrome 9.9 HLA-DQB1 TNF
48 hemorrhagic fever 9.9 HLA-DRB1 TNF
49 alveolar echinococcosis 9.9 HLA-DRB1 TNF
50 echinococcosis 9.9 HLA-DRB1 TNF

Graphical network of the top 20 diseases related to Beryllium Disease:



Diseases related to Beryllium Disease

Symptoms & Phenotypes for Beryllium Disease

Drugs & Therapeutics for Beryllium Disease

Drugs for Beryllium Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 13)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Infliximab Approved Phase 1, Phase 2 170277-31-3
2 Mesalamine Phase 1, Phase 2 89-57-6
3 Analgesics Phase 1, Phase 2
4 Peripheral Nervous System Agents Phase 1, Phase 2
5 Analgesics, Non-Narcotic Phase 1, Phase 2
6 Anti-Inflammatory Agents, Non-Steroidal Phase 1, Phase 2
7 Anti-Inflammatory Agents Phase 1, Phase 2
8 Antirheumatic Agents Phase 1, Phase 2,Phase 2
9 Dermatologic Agents Phase 1, Phase 2
10 Gastrointestinal Agents Phase 1, Phase 2
11
Heparin Approved, Investigational 9005-49-6 772 46507594
12 Pharmaceutical Solutions
13 calcium heparin

Interventional clinical trials:


# Name Status NCT ID Phase Drugs
1 Targeting Oxidative Stress in Chronic Beryllium Disease Completed NCT01088243 Phase 1, Phase 2 Mesalamine;Placebo
2 Beryllium Infliximab Study: Clinical Interventional Trial Terminated NCT00111917 Phase 1, Phase 2 Infliximab
3 The Role of JAK2 in Alveolar Macrophages (AM's) in Chronic Beryllium Disease (CBD) Unknown status NCT02596347
4 Identifying Shared Genetic Susceptibility Regions in Chronic Beryllium Disease and Sarcoidosis Completed NCT00560989
5 Exposure in Epigenetic Regulation of Immune Response in Chronic Beryllium Disease (CBD) Recruiting NCT02604693

Search NIH Clinical Center for Beryllium Disease

Genetic Tests for Beryllium Disease

Anatomical Context for Beryllium Disease

MalaCards organs/tissues related to Beryllium Disease:

41
Lung, T Cells, Testes, Skin, Bone, Heart, Spinal Cord

Publications for Beryllium Disease

Articles related to Beryllium Disease:

(show top 50) (show all 228)
# Title Authors Year
1
A Pilot Study Assessing the Ability of 5-Aminosalicylic Acid to Modulate the Immune Response in Chronic Beryllium Disease. ( 29676640 )
2018
2
5-Aminosalicylic Acid Modulates the Immune Response in Chronic Beryllium Disease Subjects. ( 29080069 )
2018
3
Effect of inhaled corticosteroids on lung function in chronic beryllium disease. ( 29453139 )
2018
4
Polymorphism of FCGR3A gene in chronic beryllium disease. ( 30245507 )
2018
5
Berylliosis (Chronic Beryllium Disease) ( 29261866 )
2017
6
Beryllium disease and sarcoidosis: still besties after all these years? ( 27246078 )
2016
7
Chronic Beryllium Disease: The Search for a Dose-Response. ( 27820771 )
2016
8
Beryllium increases the CD14(dim)CD16+ subset in the lung of chronic beryllium disease. ( 25689051 )
2015
9
Identification of multiple public TCR repertoires in chronic beryllium disease. ( 24719461 )
2014
10
Structural basis of chronic beryllium disease: linking allergic hypersensitivity and autoimmunity. ( 24995984 )
2014
11
Beryllium Biobank 3: considerations for improving chronic beryllium disease screening. ( 25099414 )
2014
12
Sarcoidosis and chronic beryllium disease: similarities and differences. ( 25007084 )
2014
13
Chronic Beryllium Disease: revealing the role of beryllium ion and small peptides binding to HLA-DP2. ( 25369028 )
2014
14
An official American Thoracic Society statement: diagnosis and management of beryllium sensitivity and chronic beryllium disease. ( 25398119 )
2014
15
Exposure factors associated with chronic beryllium disease development in Beryllium BioBank participants. ( 25099412 )
2014
16
Identification of beryllium-dependent peptides recognized by CD4+ T cells in chronic beryllium disease. ( 23797096 )
2013
17
Chronic beryllium disease: azathioprine as a possible alternative to corticosteroid treatment. ( 23277520 )
2013
18
Beryllium disease among construction trade workers at Department of Energy nuclear sites. ( 23794247 )
2013
19
Long-term efficacy of a program to prevent beryllium disease. ( 23450749 )
2013
20
Impaired function of CTLA-4 in the lungs of patients with chronic beryllium disease contributes to persistent inflammation. ( 23851684 )
2013
21
Systematic review: Progression of beryllium sensitization to chronic beryllium disease. ( 22705916 )
2012
22
Infliximab therapy modulates an antigen-specific immune response in chronic beryllium disease. ( 22974830 )
2012
23
Sensitization and chronic beryllium disease at a primary manufacturing facility, part 2: validation of historical exposures. ( 21847507 )
2012
24
Chronic beryllium disease, HLA-DPB1, and the DP peptide binding groove. ( 22972925 )
2012
25
Sensitization and chronic beryllium disease at a primary manufacturing facility, part 1: historical exposure reconstruction. ( 21850365 )
2012
26
Sensitization and chronic beryllium disease at a primary manufacturing facility, part 3: exposure-response among short-term workers. ( 21877099 )
2012
27
Risk of chronic beryllium disease by HLA-DPB1 E69 genotype and beryllium exposure in nuclear workers. ( 21471109 )
2011
28
Search for chronic beryllium disease among sarcoidosis patients in Ontario, Canada. ( 21400234 )
2011
29
Exposure and genetics increase risk of beryllium sensitisation and chronic beryllium disease in the nuclear weapons industry. ( 21460389 )
2011
30
SELDI-TOF derived serum biomarkers failed to differentiate between patients with beryllium sensitisation and patients with chronic beryllium disease. ( 21278142 )
2011
31
Chronic beryllium disease: an updated model interaction between innate and acquired immunity. ( 20981472 )
2011
32
Non-invasive diagnosis of chronic beryllium disease in workers exposed to hazardous dust in Israel. ( 19955573 )
2010
33
CC chemokine receptor 5 gene polymorphisms in beryllium disease. ( 20075058 )
2010
34
Deficient and dysfunctional regulatory T cells in the lungs of chronic beryllium disease subjects. ( 20299529 )
2010
35
Low prevalence of chronic beryllium disease among workers at a nuclear weapons research and development facility. ( 20523233 )
2010
36
Chronic beryllium disease: computed tomographic findings. ( 21084914 )
2010
37
Recent advances in understanding the biomolecular basis of chronic beryllium disease: a review. ( 19658317 )
2009
38
High extracellular induced sputum haem oxygenase-1 in sarcoidosis and chronic beryllium disease. ( 19453654 )
2009
39
Recent chronic beryllium disease in residents surrounding a beryllium facility: patients' information. ( 19119155 )
2009
40
Progression from beryllium exposure to chronic beryllium disease: an analytic model. ( 19590692 )
2009
41
A reconsideration of acute Beryllium disease. ( 19672405 )
2009
42
Beryllium lymphocyte proliferation test surveillance identifies clinically significant beryllium disease. ( 19681064 )
2009
43
Current treatment of chronic beryllium disease. ( 19894178 )
2009
44
Long-term complications and prognosis of chronic beryllium disease. ( 19960785 )
2009
45
4-1BB enhances proliferation of beryllium-specific T cells in the lung of subjects with chronic beryllium disease. ( 18768897 )
2008
46
Up-regulation of programmed death-1 expression on beryllium-specific CD4+ T cells in chronic beryllium disease. ( 18250483 )
2008
47
Impact of negatively charged patches on the surface of MHC class II antigen-presenting proteins on risk of chronic beryllium disease. ( 17956852 )
2008
48
Modulation of lymphocyte proliferation by antioxidants in chronic beryllium disease. ( 18218990 )
2008
49
Recent chronic beryllium disease in residents surrounding a beryllium facility. ( 18244954 )
2008
50
Immunology of chronic beryllium disease. ( 18317020 )
2008

Variations for Beryllium Disease

Expression for Beryllium Disease

Search GEO for disease gene expression data for Beryllium Disease.

Pathways for Beryllium Disease

Pathways related to Beryllium Disease according to GeneCards Suite gene sharing:

(show all 31)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.72 HLA-DPA1 HLA-DPB1 HLA-DQA1 HLA-DQB1 HLA-DRB1 TNF
2
Show member pathways
13.52 HLA-DPA1 HLA-DPB1 HLA-DQA1 HLA-DQB1 HLA-DRB1 TNF
3
Show member pathways
13.21 HLA-DPA1 HLA-DPB1 HLA-DQA1 HLA-DQB1 HLA-DRB1
4
Show member pathways
13.19 HLA-DPA1 HLA-DPB1 HLA-DQA1 HLA-DQB1 HLA-DRB1 TNF
5
Show member pathways
13.01 HLA-DPA1 HLA-DQA1 HLA-DQB1 HLA-DRB1 TNF
6
Show member pathways
12.79 HLA-DPA1 HLA-DPB1 HLA-DQA1 HLA-DQB1 HLA-DRB1 TNF
7
Show member pathways
12.78 HLA-DPA1 HLA-DQA1 HLA-DQB1 HLA-DRB1
8
Show member pathways
12.72 HLA-DPA1 HLA-DQA1 HLA-DQB1 HLA-DRB1
9
Show member pathways
12.71 HLA-DPA1 HLA-DPB1 HLA-DQA1 HLA-DQB1 HLA-DRB1 TNF
10
Show member pathways
12.53 HLA-DPA1 HLA-DPB1 HLA-DQA1 HLA-DQB1 HLA-DRB1 TNF
11
Show member pathways
12.49 HLA-DPA1 HLA-DPB1 HLA-DQA1 HLA-DQB1 HLA-DRB1
12
Show member pathways
12.45 HLA-DPA1 HLA-DPB1 HLA-DQA1 HLA-DQB1 HLA-DRB1 TNF
13
Show member pathways
12.33 HLA-DPA1 HLA-DPB1 HLA-DQA1 HLA-DQB1 HLA-DRB1
14
Show member pathways
12.3 HLA-DPA1 HLA-DQA1 HLA-DQB1 HLA-DRB1
15 12.29 HLA-DPA1 HLA-DPB1 HLA-DQA1 HLA-DQB1 HLA-DRB1 TNF
16
Show member pathways
12.19 HLA-DPA1 HLA-DPB1 HLA-DQA1 HLA-DQB1 HLA-DRB1
17 12.12 HLA-DPA1 HLA-DPB1 HLA-DQA1 HLA-DQB1 HLA-DRB1
18 12.1 HLA-DPA1 HLA-DPB1 HLA-DQA1 HLA-DQB1 HLA-DRB1 TNF
19 12.07 HLA-DPA1 HLA-DPB1 HLA-DQA1 HLA-DQB1 HLA-DRB1
20
Show member pathways
12.01 HLA-DPA1 HLA-DPB1 HLA-DQA1 HLA-DQB1 HLA-DRB1 TNF
21
Show member pathways
11.92 HLA-DPA1 HLA-DPB1 HLA-DQA1 HLA-DQB1 HLA-DRB1
22
Show member pathways
11.91 HLA-DPA1 HLA-DPB1 HLA-DQA1 HLA-DQB1 HLA-DRB1
23 11.9 HLA-DPA1 HLA-DPB1 HLA-DQA1 HLA-DQB1 HLA-DRB1
24 11.89 HLA-DPA1 HLA-DPB1 HLA-DQA1 HLA-DQB1 HLA-DRB1 TNF
25 11.87 HLA-DPA1 HLA-DPB1 HLA-DQA1 HLA-DQB1 HLA-DRB1
26 11.74 HLA-DPA1 HLA-DQA1 HLA-DQB1 HLA-DRB1
27 11.51 HLA-DPA1 HLA-DQA1 HLA-DQB1 HLA-DRB1
28 11.51 HLA-DPA1 HLA-DPB1 HLA-DQA1 HLA-DQB1 HLA-DRB1
29 11.42 HLA-DPA1 HLA-DPB1 HLA-DQA1 HLA-DQB1 HLA-DRB1 TNF
30 11.11 HLA-DRB1 TNF
31 11.05 HLA-DPA1 HLA-DPB1 HLA-DQA1 HLA-DQB1 HLA-DRB1 TNF

GO Terms for Beryllium Disease

Cellular components related to Beryllium Disease according to GeneCards Suite gene sharing:

(show all 18)
# Name GO ID Score Top Affiliating Genes
1 endoplasmic reticulum GO:0005783 9.88 HLA-DPA1 HLA-DPB1 HLA-DQA1 HLA-DRB1
2 Golgi membrane GO:0000139 9.88 HLA-DPA1 HLA-DPB1 HLA-DQA1 HLA-DQB1 HLA-DRB1
3 Golgi apparatus GO:0005794 9.86 HLA-DPA1 HLA-DPB1 HLA-DQA1 HLA-DRB1
4 lysosomal membrane GO:0005765 9.85 HLA-DPA1 HLA-DPB1 HLA-DQA1 HLA-DQB1 HLA-DRB1
5 endoplasmic reticulum membrane GO:0005789 9.84 HLA-DPA1 HLA-DPB1 HLA-DQA1 HLA-DRB1
6 cell surface GO:0009986 9.83 HLA-DPA1 HLA-DPB1 HLA-DRB1 TNF
7 endosome membrane GO:0010008 9.83 HLA-DPA1 HLA-DPB1 HLA-DQA1 HLA-DQB1 HLA-DRB1
8 endosome GO:0005768 9.81 HLA-DPA1 HLA-DPB1 HLA-DQA1 HLA-DRB1
9 lysosome GO:0005764 9.8 HLA-DPA1 HLA-DPB1 HLA-DQA1 HLA-DRB1
10 trans-Golgi network membrane GO:0032588 9.8 HLA-DPA1 HLA-DPB1 HLA-DQA1 HLA-DQB1 HLA-DRB1
11 endocytic vesicle membrane GO:0030666 9.77 HLA-DPA1 HLA-DPB1 HLA-DQA1 HLA-DQB1 HLA-DRB1
12 ER to Golgi transport vesicle membrane GO:0012507 9.72 HLA-DPA1 HLA-DPB1 HLA-DQA1 HLA-DQB1 HLA-DRB1
13 transport vesicle membrane GO:0030658 9.65 HLA-DPA1 HLA-DPB1 HLA-DQA1 HLA-DQB1 HLA-DRB1
14 clathrin-coated endocytic vesicle membrane GO:0030669 9.55 HLA-DPA1 HLA-DPB1 HLA-DQA1 HLA-DQB1 HLA-DRB1
15 integral component of lumenal side of endoplasmic reticulum membrane GO:0071556 9.35 HLA-DPA1 HLA-DPB1 HLA-DQA1 HLA-DQB1 HLA-DRB1
16 MHC class II protein complex GO:0042613 9.02 HLA-DPA1 HLA-DPB1 HLA-DQA1 HLA-DQB1 HLA-DRB1
17 integral component of membrane GO:0016021 10.04 HLA-DPA1 HLA-DPB1 HLA-DQA1 HLA-DQB1 HLA-DRB1 TNF
18 plasma membrane GO:0005886 10.02 HLA-DPA1 HLA-DPB1 HLA-DQA1 HLA-DQB1 HLA-DRB1 TNF

Biological processes related to Beryllium Disease according to GeneCards Suite gene sharing:

(show all 12)
# Name GO ID Score Top Affiliating Genes
1 immune response GO:0006955 9.85 HLA-DPA1 HLA-DPB1 HLA-DQA1 HLA-DQB1 HLA-DRB1 TNF
2 immune system process GO:0002376 9.78 HLA-DPA1 HLA-DPB1 HLA-DQA1 HLA-DRB1
3 T cell receptor signaling pathway GO:0050852 9.72 HLA-DPA1 HLA-DPB1 HLA-DQA1 HLA-DQB1 HLA-DRB1
4 antigen processing and presentation of exogenous peptide antigen via MHC class II GO:0019886 9.65 HLA-DPA1 HLA-DPB1 HLA-DQA1 HLA-DQB1 HLA-DRB1
5 positive regulation of interferon-gamma production GO:0032729 9.58 HLA-DPA1 HLA-DPB1 TNF
6 interferon-gamma-mediated signaling pathway GO:0060333 9.55 HLA-DPA1 HLA-DPB1 HLA-DQA1 HLA-DQB1 HLA-DRB1
7 positive regulation of T cell proliferation GO:0042102 9.51 HLA-DPA1 HLA-DPB1
8 positive regulation of T cell activation GO:0050870 9.49 HLA-DPA1 HLA-DPB1
9 humoral immune response mediated by circulating immunoglobulin GO:0002455 9.46 HLA-DQB1 HLA-DRB1
10 immunoglobulin production involved in immunoglobulin mediated immune response GO:0002381 9.43 HLA-DQB1 HLA-DRB1
11 antigen processing and presentation GO:0019882 9.35 HLA-DPA1 HLA-DPB1 HLA-DQA1 HLA-DQB1 HLA-DRB1
12 antigen processing and presentation of peptide or polysaccharide antigen via MHC class II GO:0002504 9.02 HLA-DPA1 HLA-DPB1 HLA-DQA1 HLA-DQB1 HLA-DRB1

Molecular functions related to Beryllium Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 MHC class II receptor activity GO:0032395 9.26 HLA-DPA1 HLA-DQA1 HLA-DQB1 HLA-DRB1
2 peptide antigen binding GO:0042605 9.02 HLA-DPA1 HLA-DPB1 HLA-DQA1 HLA-DQB1 HLA-DRB1

Sources for Beryllium Disease

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....